EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality

Area of Science:

• Oncology
• Pharmacology
• Translational Medicine

Background:

• Preclinical studies show synergy between epidermal growth factor receptor (EGFR)-targeting drugs and cytotoxic agents.
• Clinical trials have revealed significant gaps between preclinical findings and patient responses, especially in non-small cell lung cancer (NSCLC).
• Tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib combined with chemotherapy have shown limited success in pretreated NSCLC patients.

Purpose of the Study:

• To critically examine preclinical experimental conditions for EGFR-targeted drug and cytotoxic agent combinations.
• To elucidate the reasons for discrepancies between preclinical data and clinical observations.
• To explore how understanding acquired resistance can improve the clinical effectiveness of these drug combinations.

Main Methods:

• Review of preclinical models and methodologies used to evaluate drug combinations.
• Analysis of factors contributing to the bench-to-bedside gap, including drug sequencing.
• Examination of recent advances in understanding acquired resistance mechanisms.

Main Results:

• Methodological variations in preclinical studies may not accurately predict clinical outcomes.
• Insufficient consideration of drug sequencing in preclinical evaluations contributes to discrepancies.
• Understanding acquired resistance is crucial for optimizing combination therapies.

Conclusions:

• The preclinical evaluation of EGFR-targeted drugs and cytotoxic agent combinations requires refinement.
• Drug sequencing and resistance mechanisms are critical factors influencing clinical efficacy.
• Bridging the gap between preclinical research and clinical practice is essential for improving cancer treatment.